The Shuman Law Firm Investigates BioScrip, Inc.
April 01 2015 - 05:00PM
Business Wire
The Shuman Law Firm announces that it is investigating potential
claims against certain officers and directors of BioScrip, Inc.
(“BioScrip” or the “Company”) (Nasdaq: BIOS). BioScrip is a New
York-based company that provides home infusion and other home care
services, and pharmacy benefit management services in the United
States.
The Firm’s investigation relates to a U.S. Department of Justice
Press Release which disclosed that BioScrip has agreed to forfeit
$15 million for the Company’s participation in a kickback scheme
with Novartis Pharmaceuticals, Inc. Following the public disclosure
of these events, BioScrip stockholders filed a class action lawsuit
against the Company in U.S. District Court Southern District of New
York alleging that the Company had made false and misleading
statements in its public Securities Exchange Commission (SEC)
filings. On March 31, 2015, the federal judge denied, in part, the
defendants’ motion to dismiss the complaint, and the case is
proceeding towards trial.
If you currently own BioScrip common stock and are interested in
discussing your rights, or have information relating to this
investigation, please contact Kip B. Shuman or Rusty E. Glenn
toll-free at (866) 569-4531 or email Mr. Shuman at
kip@shumanlawfirm.com or email Mr. Glenn at
rusty@shumanlawfirm.com.
The Shuman Law Firm represents investors throughout the nation,
concentrating its practice in stockholder litigation.
The Shuman Law FirmKip B. Shuman, Esq.,
303-861-3003kip@shumanlawfirm.comorRusty E. Glenn, Esq.,
303-861-3003rusty@shumanlawfirm.comorToll-Free: 866-569-4531Fax:
303-536-7849www.shumanlawfirm.com
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2023 to Mar 2024